3.5(top 10%)
impact factor
1.4K(top 20%)
papers
17.0K(top 10%)
citations
48(top 10%)
h-index
3.8(top 10%)
extended IF
1.5K
all documents
19.6K
doc citations
95(top 10%)
g-index

Top Articles

#TitleJournalYearCitations
1OncoKB: A Precision Oncology Knowledge BaseJCO Precision Oncology20171,422
2Landscape of Microsatellite Instability Across 39 Cancer TypesJCO Precision Oncology2017884
3Next-Generation Sequencing Directs Therapy and Delineates a Clonal Relationship in Mast Cell Sarcoma and Acute Myeloid LeukemiaJCO Precision Oncology2019429
4Intermittent Treatment With MEK Inhibitors in Patients With Oncogenic RAF-Driven Tumors: A Potential Strategy to Manage Toxicity and Maintain EfficacyJCO Precision Oncology2018343
5Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision MakingJCO Precision Oncology2017313
6Acral Lentiginous Melanoma Harboring a ROS1 Gene Fusion With Clinical Response to EntrectinibJCO Precision Oncology2017311
7PTEN Loss-of-Function Alterations Are Associated With Intrinsic Resistance to BRAF Inhibitors in Metastatic MelanomaJCO Precision Oncology2017279
8Prevalence of Homologous Recombination–Related Gene Mutations Across Multiple Cancer TypesJCO Precision Oncology2018241
9Reliable Pan-Cancer Microsatellite Instability Assessment by Using Targeted Next-Generation Sequencing DataJCO Precision Oncology2017233
10Analysis of NTRK Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for NTRK-Targeted TherapeuticsJCO Precision Oncology2018225
11Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non–Small-Cell Lung CancerJCO Precision Oncology2017177
12CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 InhibitorsJCO Precision Oncology2020154
13Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA MutationJCO Precision Oncology2018136
14Clinicopathologic Features of Non–Small-Cell Lung Cancer Harboring an NTRK Gene FusionJCO Precision Oncology2018128
15Economic Impact of Next-Generation Sequencing Versus Single-Gene Testing to Detect Genomic Alterations in Metastatic Non–Small-Cell Lung Cancer Using a Decision Analytic ModelJCO Precision Oncology2019120
16Breast and Ovarian Cancer Penetrance Estimates Derived From Germline Multiple-Gene Sequencing Results in WomenJCO Precision Oncology2017117
17Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine StudyJCO Precision Oncology2017114
18Clinical Value of RNA Sequencing–Based Classifiers for Prediction of the Five Conventional Breast Cancer Biomarkers: A Report From the Population-Based Multicenter Sweden Cancerome Analysis Network—Breast InitiativeJCO Precision Oncology2018113
19Pan-Cancer Analysis of BRCA1 and BRCA2 Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of HeterozygosityJCO Precision Oncology2020112
20Dramatic Response to Crizotinib in a Patient With Lung Cancer Positive for an HLA-DRB1-MET Gene FusionJCO Precision Oncology2017111
21Cholangiocarcinoma With FGFR Genetic Aberrations: A Unique Clinical PhenotypeJCO Precision Oncology2018108
22Rationale and Design of the Targeted Agent and Profiling Utilization Registry StudyJCO Precision Oncology2018108
23Orthogonal Comparison of Four Plasma NGS Tests With Tumor Suggests Technical Factors are a Major Source of Assay DiscordanceJCO Precision Oncology2019106
24Platinum-Based Chemotherapy in Metastatic Prostate Cancer With DNA Repair Gene AlterationsJCO Precision Oncology2020104
25Detection of Somatic Structural Variants Enables Quantification and Characterization of Circulating Tumor DNA in Children With Solid TumorsJCO Precision Oncology201899
26Programmed Cell Death 1 (PD-1) Ligand (PD-L1) Expression in Solid Tumors As a Predictive Biomarker of Benefit From PD-1/PD-L1 Axis Inhibitors: A Systematic Review and Meta-AnalysisJCO Precision Oncology201790
27Use of Next-Generation Sequencing Tests to Guide Cancer Treatment: Results From a Nationally Representative Survey of Oncologists in the United StatesJCO Precision Oncology201890
28Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors Through Longitudinal Analysis of Circulating Tumor DNAJCO Precision Oncology201888
29Immunophenotype and Response to Immunotherapy of RET-Rearranged Lung CancersJCO Precision Oncology201983
30Targeting HER2 Alterations in Non–Small-Cell Lung Cancer: A Comprehensive ReviewJCO Precision Oncology202080
31Prospective Comprehensive Genomic Profiling of Primary and Metastatic Prostate TumorsJCO Precision Oncology201977
32Detection of Early Human Papillomavirus–Associated Cancers by Liquid BiopsyJCO Precision Oncology201975
33Outcomes of BRAF V600E Pediatric Gliomas Treated With Targeted BRAF InhibitionJCO Precision Oncology202071
34Model Combining Tumor Molecular and Clinicopathologic Risk Factors Predicts Sentinel Lymph Node Metastasis in Primary Cutaneous MelanomaJCO Precision Oncology202070
35Validation of HER2 Amplification as a Predictive Biomarker for Anti–Epidermal Growth Factor Receptor Antibody Therapy in Metastatic Colorectal CancerJCO Precision Oncology201969
36Homologous Recombination Deficiency in Breast Cancer: A Clinical ReviewJCO Precision Oncology201768
37Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non–Small-Cell Lung CancerJCO Precision Oncology201968
38Acquired ALK and RET Gene Fusions as Mechanisms of Resistance to Osimertinib in EGFR-Mutant Lung CancersJCO Precision Oncology201867
39Circulating Tumor DNA Analysis and Functional Imaging Provide Complementary Approaches for Comprehensive Disease Monitoring in Metastatic MelanomaJCO Precision Oncology201765
40BOIN12: Bayesian Optimal Interval Phase I/II Trial Design for Utility-Based Dose Finding in Immunotherapy and Targeted TherapiesJCO Precision Oncology202065
41Majority of B2M-Mutant and -Deficient Colorectal Carcinomas Achieve Clinical Benefit From Immune Checkpoint Inhibitor Therapy and Are Microsatellite Instability-HighJCO Precision Oncology201964
42Personalized Medicine in the Oncology Clinic: Implementation and Outcomes of the Johns Hopkins Molecular Tumor BoardJCO Precision Oncology201761
43Stromal Content Is Correlated With Tissue Site, Contrast Retention, and Survival in Pancreatic AdenocarcinomaJCO Precision Oncology201860
44Comparative Analysis of Durable Responses on Immune Checkpoint Inhibitors Versus Other Systemic Therapies: A Pooled Analysis of Phase III TrialsJCO Precision Oncology201960
45METExon 14 Skipping Mutations in Non–Small-Cell Lung Cancer: An Overview of Biology, Clinical Outcomes, and Testing ConsiderationsJCO Precision Oncology202160
46Detection of Molecular Residual Disease Using Personalized Circulating Tumor DNA Assay in Patients With Colorectal Cancer Undergoing Resection of MetastasesJCO Precision Oncology202160
47CDK12-Mutated Prostate Cancer: Clinical Outcomes With Standard Therapies and Immune Checkpoint BlockadeJCO Precision Oncology202056
48Palbociclib in Patients With Pancreatic and Biliary Cancer WithCDKN2AAlterations: Results From the Targeted Agent and Profiling Utilization Registry StudyJCO Precision Oncology201954
49Palbociclib in Patients With Non–Small-Cell Lung Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry StudyJCO Precision Oncology202054
50Tumor-Infiltrating Lymphocyte Function Predicts Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal CancerJCO Precision Oncology201853